SLAMF7 and plasma cell myeloma: It exerts its effect via a dual mechanism of action: direct activation of NK cells and ADCC via SLAMF7 ligation in which the Fc portion of elotuzumab binds to the activating Fc receptor (CD16) on NK cells, whereas the Fab portion of elotuzumab binds to SLAMF7 on myeloma cells [74,75].